Pfizer’s Effort To Remove Chantix Boxed Warning May Backfire
This article was originally published in The Pink Sheet Daily
Most FDA advisory committee members vote to wait until clinical trial results are submitted, but some also say warning should be include additional adverse events.
You may also be interested in...
Pfizer, GSK score as neuropsychiatric symptom risks now only appear in Warnings and Precautions section following EAGLES trial results.
Advisory committee says data supports dialing back safety label for the smoking cessation product, but shouldn’t be precedent setting.
FDA will present concerns on data collection and study conduct during advisory committee meeting on removing smoking cessation drug's boxed warning.